A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection.

Abstract:

:Knowledge about long-term consequences of breast cancer treatment on shoulder and arm function and volume in stages I-II breast cancer survivors is limited. The effects of shoulder-arm function shortly after surgery on long-term function are unknown. One hundred and ninety-four women were examined pre-surgery (T0) and 6 weeks after surgery (T1). Of those, 110 were re-examined 7 years later (T2). Thirty-four women underwent sentinel lymph node biopsy (SLNB) and 76 underwent axillary lymph node dissection (ALND). Differences between affected and unaffected side were calculated for four ranges of motion functions, three strength functions and arm volume. These were used to analyse time and group effects. Differences exceeding 20° in range of motion, 20 % in strength and 200 ml in arm volume were considered clinically relevant. Multivariate regression analyses examined the effect of shoulder-arm function at T1 on shoulder-arm function at T2. Additional predictor variables included were age, follow-up time, Body Mass Index, complications, chemotherapy, radiation, SLNB/ALND and type of breast surgery. At T2, range of motion (except external rotation), abduction strength and arm volume were impaired compared to T0. After ALND, women had significantly more forward flexion impairment, increased arm volume and clinically relevant impairments (70 %) than after SLNB (41 %). T1 external rotation, abduction-external rotation, grip strength and arm volume were the strongest predictors of these variables at T2. Age was the strongest predictor of the remaining four variables. ALND predicted arm volume only. Seven years after breast cancer surgery, two-fifth of the women after SLNB and seven out of ten women after ALND had impairments. Impairments were found in five of eight shoulder-arm functions. After SLNB, women have less forward flexion impairment and less arm volume increase than after ALND. Shoulder-arm function at 6 weeks after surgery and age are the strongest predictors of long-term shoulder-arm function.

authors

Kootstra JJ,Dijkstra PU,Rietman H,de Vries J,Baas P,Geertzen JH,Hoekstra HJ,Hoekstra-Weebers JE

doi

10.1007/s10549-013-2509-y

subject

Has Abstract

pub_date

2013-05-01 00:00:00

pages

125-34

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

139

pub_type

杂志文章
  • Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed.

    abstract:PURPOSE:Evaluation of the safety and efficacy of a combination of docetaxel and doxorubicin in breast cancer patients. Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of defin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9889-9

    authors: Mukai H,Watanabe T,Ando M,Shimizu C,Katsumata N

    更新日期:2009-01-01 00:00:00

  • Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.

    abstract::Our previous study found cancer detection rates were equivalent for direct radiography compared to screen-film mammography, while rates for computed radiography were significantly lower. This study compares prognostic features of invasive breast cancers by type of mammography. Approved by the University of Toronto Res...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3088-2

    authors: Prummel MV,Done SJ,Muradali D,Majpruz V,Brown P,Jiang H,Shumak RS,Yaffe MJ,Holloway CM,Chiarelli AM

    更新日期:2014-09-01 00:00:00

  • Medical costs associated with metastatic breast cancer in younger, midlife, and older women.

    abstract:PURPOSE:We estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal. METHODS:We used 2003-2014 North Carolina cancer registry data linked with administrative claims fro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05654-x

    authors: Trogdon JG,Baggett CD,Gogate A,Reeder-Hayes KE,Rotter J,Zhou X,Ekwueme DU,Fairley TL,Wheeler SB

    更新日期:2020-06-01 00:00:00

  • Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

    abstract::Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0469-z

    authors: Brown M,Bauer K,Pare M

    更新日期:2010-02-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract::The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01803781

    authors: Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期:1996-01-01 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract::The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9312-y

    authors: Paliouras M,Diamandis EP

    更新日期:2007-03-01 00:00:00

  • Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

    abstract::Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women in...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-009-0309-1

    authors: Henry NL,Rae JM,Li L,Azzouz F,Skaar TC,Desta Z,Sikora MJ,Philips S,Nguyen AT,Storniolo AM,Hayes DF,Flockhart DA,Stearns V,Consortium on Breast Cancer Pharmacogenomics Investigators.

    更新日期:2009-10-01 00:00:00

  • A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family.

    abstract::We report a novel germline 5369delATTT mutation in BRCA2 gene, detected in a 45-year-old woman with bilateral breast cancer. This deletion was also detected in her father with prostatic cancer and her sister with breast cancer. The mutation originates a premature stop at codon 1723 of BRCA2 protein and has not been do...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0361-x

    authors: Salgado J,Aramendía JM,Gutierrez C,Gil C,Robles M,García-Foncillas J

    更新日期:2010-05-01 00:00:00

  • Syndecan-1 facilitates breast cancer metastasis to the brain.

    abstract:PURPOSE:Although survival rates for patients with localized breast cancer have increased, patients with metastatic breast cancer still have poor prognosis. Understanding key factors involved in promoting breast cancer metastasis is imperative for better treatments. In this study, we investigated the role of syndecan-1 ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05347-0

    authors: Sayyad MR,Puchalapalli M,Vergara NG,Wangensteen SM,Moore M,Mu L,Edwards C,Anderson A,Kall S,Sullivan M,Dozmorov M,Singh J,Idowu MO,Koblinski JE

    更新日期:2019-11-01 00:00:00

  • Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.

    abstract:PURPOSE:Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcome...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05352-3

    authors: Aleixo GFP,Williams GR,Nyrop KA,Muss HB,Shachar SS

    更新日期:2019-10-01 00:00:00

  • False-negative rate of combined mammography and ultrasound for women with palpable breast masses.

    abstract::Mammography and ultrasound are often used concurrently for patients with palpable breast masses. While mammography has a false-negative rate of approximately 15 %, the addition of breast ultrasound decreases this rate among patients with palpable breast masses. There are no recent outcome data regarding the use of com...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3557-2

    authors: Chan CH,Coopey SB,Freer PE,Hughes KS

    更新日期:2015-10-01 00:00:00

  • Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women.

    abstract::Elevated levels of circulating estrogens and androgens are linked to higher breast cancer risk among postmenopausal women; however, little is known about hormone levels within the breast. Hormone concentrations within the breast may not be reflected in the blood and are likely important contributors to breast carcinog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1734-5

    authors: Falk RT,Gentzschein E,Stanczyk FZ,Garcia-Closas M,Figueroa JD,Ioffe OB,Lissowska J,Brinton LA,Sherman ME

    更新日期:2012-01-01 00:00:00

  • Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

    abstract::Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry (ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this study was to disclose the prognostic significance of different morphological categories of ICC-positive cells according to treatment status an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2439-8

    authors: Synnestvedt M,Borgen E,Schlichting E,Schirmer CB,Renolen A,Giercksky KE,Nesland JM,Naume B

    更新日期:2013-04-01 00:00:00

  • Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.

    abstract::We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005716214718

    authors: Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

    更新日期:1997-01-01 00:00:00

  • Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone

    abstract:BACKGROUND:This study evaluated the cost-effectiveness of anastrozole versus generic tamoxifen for primary adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC), from a US healthcare perspective. METHODS:A probabilistic Markov model was developed using the 5-year com...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9483-6

    authors: Locker GY,Mansel R,Cella D,Dobrez D,Sorensen S,Gandhi SK,ATAC Trialists' Group.

    更新日期:2007-12-01 00:00:00

  • Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

    abstract::Triple-negative breast cancer (TNBC) is a subtype of breast tumor with unique characteristics in terms of clinical-pathological presentation, prognosis, and response to therapy. Epidemiological investigations focusing on the identification of risk factors involved in the onset and progression of TNBCs have identified ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2339-3

    authors: Pierobon M,Frankenfeld CL

    更新日期:2013-01-01 00:00:00

  • Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.

    abstract::Anthracyclines are among the most powerful antineoplastic drugs available for breast cancer treatment. Although HER2 amplification has been postulated to predict anthracycline benefit, numerous reports have demonstrated that HER2/TOP2A co-amplification is the clinically useful predictive marker of response to anthracy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2791-8

    authors: García-Caballero T,Prieto O,Vázquez-Boquete A,Gude F,Viaño P,Otero M,Curiel T,Fernández-Rodríguez B,Parrado C,Fraga M,Antúnez JR

    更新日期:2014-01-01 00:00:00

  • Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.

    abstract::Chromosomal instability is a known hallmark of many cancers. DNA polymerases represent a group of enzymes that are involved in the mechanism of chromosomal instability as they have a central function in DNA metabolism. We hypothesized that genetic variation in the polymerase genes may affect gene expression or protein...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1460-z

    authors: Varadi V,Bevier M,Grzybowska E,Johansson R,Enquist K,Henriksson R,Butkiewicz D,Pamula-Pilat J,Tecza K,Hemminki K,Lenner P,Försti A

    更新日期:2011-08-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract:PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-020-05648-9

    authors: Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期:2020-07-01 00:00:00

  • Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

    abstract::Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot co...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10549-011-1612-1

    authors: Hadad S,Iwamoto T,Jordan L,Purdie C,Bray S,Baker L,Jellema G,Deharo S,Hardie DG,Pusztai L,Moulder-Thompson S,Dewar JA,Thompson AM

    更新日期:2011-08-01 00:00:00

  • Dual HER2-targeted approaches in HER2-positive breast cancer.

    abstract::Approximately 15-20% of all breast cancers are human epidermal growth factor receptor 2 (HER2) positive, with clinical studies having validated the HER2 receptor tyrosine kinase pathway as an important therapeutic target. Presently, two HER2-targeted therapies are approved by the Food and Drug Administration for treat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-011-1781-y

    authors: Ahn ER,Vogel CL

    更新日期:2012-01-01 00:00:00

  • Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.

    abstract:PURPOSE:Psychological resilience is an important ability for women with breast cancer to cope effectively with depression and anxiety. However, the demands of long-term hospital-based psychological rehabilitation interventions are not met in mainland China, where shorter hospital stays and longer home rehabilitation ar...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05368-9

    authors: Zhou K,Li J,Li X

    更新日期:2019-11-01 00:00:00

  • Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.

    abstract:UNLABELLED:Taxanes and anthracyclines improve the outcome of early breast cancer, although the benefit is limited to a small proportion of patients and are toxic. We prospectively looked for predictors of response to these drugs. EXPERIMENTAL DESIGN:Four cycles of doxorubicin (75 mg/m²) or docetaxel (100 mg/m²) were c...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-011-1461-y

    authors: Martin M,Romero A,Cheang MC,López García-Asenjo JA,García-Saenz JA,Oliva B,Román JM,He X,Casado A,de la Torre J,Furio V,Puente J,Caldés T,Vidart JA,Lopez-Tarruella S,Diaz-Rubio E,Perou CM

    更新日期:2011-07-01 00:00:00

  • Loss of BRCA1 expression in sporadic male breast carcinoma.

    abstract::BRCA1 protein is normally expressed in the nuclei of breast epithelial cells and functions as a negative regulator of the cell cycle. Mutations of BRCA1 gene have been associated with familial breast carcinomas. Although somatic mutations have not been demonstrated in sporadic breast carcinomas, loss of nuclear expres...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1013317909431

    authors: Sun X,Gong Y,Rao MS,Badve S

    更新日期:2002-01-01 00:00:00

  • Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).

    abstract:PURPOSE:The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the n...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-017-4318-1

    authors: Vidula N,Yau C,Li J,Esserman LJ,Rugo HS

    更新日期:2017-08-01 00:00:00

  • Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

    abstract::To evaluate differences in use of sentinel lymph node biopsy (SLNB) by age and race in Medicare recipients with early-stage breast cancer, we examined Surveillance, Epidemiology and End Results-Medicare linked data for women undergoing breast conserving surgery for stage I or II breast cancer, including axillary stagi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1398-1

    authors: Reeder-Hayes KE,Bainbridge J,Meyer AM,Amos KD,Weiner BJ,Godley PA,Carpenter WR

    更新日期:2011-08-01 00:00:00

  • Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.

    abstract::The Women's Health Initiative (WHI) randomized trials found that use of combined estrogen and progestin menopausal hormone therapy (CHT) increases breast cancer risk, but use of unopposed estrogen hormone therapy (EHT) does not. However, several questions regarding the impact of hormone use on risk of different types ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2960-4

    authors: Li CI,Daling JR,Haugen KL,Tang MT,Porter PL,Malone KE

    更新日期:2014-06-01 00:00:00

  • The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

    abstract::The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it wi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3308-4

    authors: Jerjees DA,Negm OH,Alabdullah ML,Mirza S,Alkaabi M,Hameed MR,Abduljabbar R,Muftah A,Nolan CC,Green AR,Tighe PJ,Band V,Ellis IO,Rakha EA

    更新日期:2015-02-01 00:00:00

  • The histopathological and molecular features of breast carcinoma with tumour budding-a systematic review and meta-analysis.

    abstract:PURPOSE:Tumour budding (TB) is an adverse histological feature in many epithelial cancers. It is thought to represent epithelial-mesenchymal transition, a key step in the metastatic process. The significance of TB in breast carcinoma (BC) remains unclear. The aim of this study is to investigate the relationship between...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-05810-3

    authors: Lloyd AJ,Ryan ÉJ,Boland MR,Elwahab SA,Malone C,Sweeney KJ,Barry KM,McLaughlin R,Kerin MJ,Lowery AJ

    更新日期:2020-10-01 00:00:00

  • Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up.

    abstract::Chemotherapy-induced alopecia is a commonly feared chemotherapy side effect and can be prevented using scalp cooling. Scalp metastasis is a rare site of recurrence. There is a question about whether or not the risk might be increased with the use of scalp cooling. Two cases of breast cancer with scalp metastases as fi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1453-y

    authors: Lemieux J,Desbiens C,Hogue JC

    更新日期:2011-07-01 00:00:00